Finished
Combined Vaginal Misoprostol and Perivascular Vasopressin
NCT03815344 · Antonios Likourezos · Updated 9 Jan 2024
- What is being tested
- Standard; Standard-vaginal misoprostol
- For
- Leiomyoma; Laparoscopy; Uterine Myomectomy
- Kind of study
- Tests a treatment or device on volunteers. Phase 4.
- Who can join
- Ages 18 years to 55 years. About 74 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 26 April 2017, ends 30 June 2019. Registered 24 Jan 2019.
- Results
- Posted on the registry on 9 Jan 2024.
In the researchers' words
Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal. Additionally, Misoprostol has been looked at as an additional method to decrease operative blood loss given its ability to increase uterine muscle tone, which therefore constricts the amount of blood flow to the uterus.
Sites
- Maimonides Medical CenterBrooklyn, New York, United States